TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zelira Therapeutics ( (AU:ZLD) ) has issued an update.
Zelira Therapeutics has received a $1,070,000 cash refund from the Australian Federal Government’s R&D Tax Incentive Scheme. This refund will support the company’s ongoing clinical and product development programs, as well as initiatives for pipeline products and essential business operations, thereby strengthening its position in the cannabis medicine industry.
The most recent analyst rating on (AU:ZLD) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics is a global leader in the development of clinically validated cannabis medicines. The company focuses on creating innovative cannabis-based therapies and products, targeting a wide range of medical conditions.
Average Trading Volume: 5,836
Technical Sentiment Signal: Sell
Current Market Cap: A$4.16M
See more insights into ZLD stock on TipRanks’ Stock Analysis page.